"Suzetrigine’s non-opioid mechanism eliminates risks of misuse, addiction and respiratory depression, making it a safer alternative for acute pain management." In addition to acute pain ...

Acute pain management in the older adult is both challenging and rewarding. This review addresses the difficulty with assessment of pain in the older adult, variations in the pain experience of ...

Acute pain is reported in nearly 60% of pediatric emergency department (ED) visits, Olejnik and colleagues noted, and "clinical management of acute pain remains variable," with opioids often given ...

Opioids like sufentanil and remifentanil during surgery may worsen post-surgery pain, highlighting the need for a review of ...

Pain management continues to be a priority animal welfare issue, particularly as updates to the beef cattle code of practice ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

Novant Health Inc. has opened a clinic in Stokesdale focused on acute and chronic pain management. The facility is located at 7779 N.C. 68, Suite 2A, near Stokesdale Town Park.

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

When necessary, naloxone (an opioid antagonist) can be administered. Naloxone can cause opioid withdrawal, sudden severe pain, hypertension and pulmonary edema. The manufacturer of naloxone ...